SQUAWK/NEWS
Account
Account
Menu
Live News EQUITY FLASH M impact

Sanofi: Wayrilz Approved

Sanofi's Wayrilz is approved in Japan for immune thrombocytopenia based on the Luna 3 Phase 3 study

SNY

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.